<?xml version="1.0" encoding="UTF-8"?>
<p id="p0705">Strongyloidiasis should be considered in patients with a relevant travel history or migration from an endemic area and compatible symptoms or persistent, unexplained eosinophilia. Expert opinion favors screening patients from endemic areas or with unexplained eosinophilia before starting treatment with biological therapies [
 <xref rid="bib58" ref-type="bibr">58</xref>].
</p>
